Ewing's sarcoma fusion protein, EWS/Fli-1 and Fli-1 protein induce PLD2 but not PLD1 gene expression by binding to an ETS domain of 5′ promoter

Oncogene

Volumn 26, Issue 12, 2007, Pages 1802-1810

  Kikuchi, R ^a   Murakami, M ^a   Sobue, S ^a   Iwasaki, T ^a,b   Hagiwara, K ^c   Takagi, A ^a   Kojima, T ^a   Asano, H ^d   Suzuki, M ^a   Banno, Y ^e   Nozawa, Y ^f   Murate, T ^a,g  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^d CHUBU UNIVERSITY   (Japan)

^e GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f GIFU INTERNATIONAL INSTITUTE OF BIOTECHNOLOGY   (Japan)

^g NAGOYA UNIVERSITY   (Japan)

Author keywords

Ewing's sarcoma; EWS Fli 1; Gene expression; PLD; Promoter analysis

Indexed keywords

BUTANOL; HYBRID PROTEIN; PHOSPHOLIPASE D1; PHOSPHOLIPASE D2; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR ELK 1; TRANSCRIPTION FACTOR FLI 1;

ARTICLE; CAPILLARY ELECTROPHORESIS; CELL CLONE; CELL GROWTH; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DNA BINDING; ERYTHROBLAST; EWING SARCOMA; GEL MOBILITY SHIFT ASSAY; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; PROTEIN DOMAIN; PROTEIN INDUCTION; PROTEIN RNA BINDING; TRANSACTIVATION; TRANSCRIPTION INITIATION; TRANSCRIPTION INITIATION SITE;

BASE SEQUENCE; CELL LINE; DNA PRIMERS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HUMANS; IMMUNOPRECIPITATION; MICROFILAMENT PROTEINS; ONCOGENE PROTEINS, FUSION; PHOSPHOLIPASE D; PROMOTER REGIONS (GENETICS); PROTEIN BINDING; PROTO-ONCOGENE PROTEIN C-FLI-1; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION;

EID: 33947203277     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209973     Document Type: Article

References (22)

1. Arvand A, Denny CT. (2001). Biology of EWS/ETS fusions in Ewing's family tumors. Oncogene 20: 5747-5754.
2. Banno Y, Fujita H, Ono Y, Nakashima S, Ito Y, Kuzumaki et al. (1999). Differential phospholipase D activation by bradykinin and sphingosine 1-phosphate in NIH 3T3 fibroblasts overexpressing gelsolin. J Biol Chem 274: 27385-27391.
3. Carnero A, Cuadrado A, del Peso L, Lacal JC. (1994). Activation of type D phospholipase by serum stimulation and ras-induced transformation in NIH3T3 cells. Oncogene 9: 1387-1395.
4. Dauphinot L, De Oliveira C, Melot T, Sevenet N, Thomas V, Weissman BE et al. (2001). Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2 and c-Myc expression. Oncogene 20: 3258-3265.
5. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M et al. (1992). Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumors. Nature 359: 162-165.
6. Exton JH. (2002). Phospholipase D-structure, regulation and function. Rev Physiol Biochem Pharmacol 144: 1-94.
7. Foster DA, Xu L. (2003). Phospholipase D in cell proliferation and cancer. Mol Cancer Res 1: 789-800.
8. Graves BJ, Petersen JM. (1998). Specificity within the ETS family of transcription factors. Adv Cancer Res 75: 1-55.
9. Liscovitch M, Czarny M, Fiucci G, Tang X. (2000). Phospholipase D: molecular and cell biology of a novel gene family. Biochem J 345: 410-415.
10. Mao X, Miesfeldt S, Yang H, Leiden JM, Thompson CB. (1994). The FLI-1 and chimeric EWS-FLI-1 oncoproteins display similar DNA binding specificities. J Biol Chem 269: 18216-18222.
11. Nakade Y, Banno Y, T-Koizumi K, Hagiwara K, Sobue S, Koda M et al. (2003). Regulation of sphingosine kinase 1 gene expression by protein kinase C in a human leukemia cell line, MEG-O1. Biochim Biophys Acta 1635: 104-116.
12. Nozawa S, Ohno T, Banno Y, Dohjima T, Wakahara K, Fan DG et al. (2005). Inhibition of platelet-derived growth factor-induced cell growth signaling by a short interfering RNA for EWS-Fli-1 via down-regulation of phospholipase D2 in Ewing sarcoma cells. J Biol Chem 280: 27544-27551.
13. Oikawa T. (2004). ETS transcription factors: possible targets for cancer therapy. Cancer Sci 95: 626-633.
14. Prieur A, Tirode F, Cohen P, Delattre O. (2004). EWS/Fli-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol 24: 7275-7283.
15. Ramugounder R, Yasuo F, Zou JP, Liu F, Lee L, Rao VN et al. (2004). Role of protein - protein interactions in the antiapoptotic function of EWS-Fli-1. Oncogene 23: 1-8.
16. Redina OE, Frohman MA. (1998a). Genomic analysis of murine phospholipase D1 and comparison to phospholipase D2 reveals an unusual difference in gene size. Gene 222: 53-60.
17. Redina OE, Frohman MA. (1998b). Organization and alternative splicing of the murine phsopholipase D2 gene. Biochem J 331: 173-177.
18. Sementchenko VI, Watson DK. (2000). Ets target genes: past, present and future. Oncogene 19: 6533-6548.
19. Sobue S, Hagiwara K, Banno Y, Tamiya-Koizumi K, Suzuki M, Takagi A et al. (2005). Transcription factor specificity protein 1 (Sp1) is the main regulator of nerve growth factor-induced sphingosine kinase 1 gene expression of the rat pheochromocytoma cell line, PC12. J Neurochem 95: 940-949.
20. Toretsky JA, Connell Y, Neckers L, Bhat NK. (1997). Inhibition of EWS-Fli-1 fusion protein with antisense oligodeoxynucleotides. J Neurooncol 31: 9-16.
21. Truong AH, Ben-David Y. (2000). The role of Fli-1 in normal cell function and malignant transformation. Oncogene 19: 6482-6489.
22. Zhao Y, Ehara H, Akao Y, Shamoto M, Nakagawa Y, Banno Y et al. (2000). Increased activity and intranuclear expression of phospholipase D2 in human renal cancer. Biochem Biophys Research Commun 278: 140-143.